Efficacy and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events and Safety Outcomes in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population-based Target Trial Emulation

IF 11.4 1区医学 Q1 RHEUMATOLOGY

Arthritis & Rheumatology Pub Date : 2024-10-21 DOI:10.1002/art.43037

Kevin Sheng-Kai Ma, Jui-En Lo, Vasileios C. Kyttaris, George C. Tsokos, Karen H. Costenbader

引用次数: 0

Abstract

Patients with systemic lupus erythematosus (SLE) were excluded from sodium-glucose co-transporter 2 inhibitors (SGLT2i) clinical trials. It is unknown whether the cardiorenal benefits of SGLT2i extend to patients with SLE and comorbid type 2 diabetes (T2D).

查看原文本刊更多论文

钠-葡萄糖协同转运体 2 抑制剂用于系统性红斑狼疮合并 2 型糖尿病患者心血管和肾脏事件一级预防的有效性和安全性以及安全结果：基于人群的目标试验模拟

系统性红斑狼疮（SLE）患者被排除在钠-葡萄糖协同转运体 2 抑制剂（SGLT2i）临床试验之外。SGLT2i对系统性红斑狼疮和合并2型糖尿病（T2D）患者的心肾功能是否有益处尚不清楚。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arthritis & Rheumatology RHEUMATOLOGY-

CiteScore

20.90

自引率

3.00%

发文量

371

期刊介绍： Arthritis & Rheumatology is the official journal of the American College of Rheumatology and focuses on the natural history, pathophysiology, treatment, and outcome of rheumatic diseases. It is a peer-reviewed publication that aims to provide the highest quality basic and clinical research in this field. The journal covers a wide range of investigative areas and also includes review articles, editorials, and educational material for researchers and clinicians. Being recognized as a leading research journal in rheumatology, Arthritis & Rheumatology serves the global community of rheumatology investigators and clinicians.